{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:40:22Z","timestamp":1793997622244,"version":"4.8.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018617","name":"Liaoning Revitalization Talents Program","doi-asserted-by":"publisher","award":["XLYC1908031"],"award-info":[{"award-number":["XLYC1908031"]}],"id":[{"id":"10.13039\/501100018617","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFE0111300"],"award-info":[{"award-number":["2024YFE0111300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFE0201700"],"award-info":[{"award-number":["2020YFE0201700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.canlet.2026.218242","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T15:48:53Z","timestamp":1767455333000},"page":"218242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["A Pt (IV)\/losartan\/immunotherapy Co-delivery thermosensitive gel synergizes STING activation and cancer-associated fibroblast inhibition for ovarian cancer chemoimmunotherapy"],"prefix":"10.1016","volume":"639","author":[{"given":"Boyuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhitao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3796-3413","authenticated-orcid":false,"given":"Zixu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunwen","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxin","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.canlet.2026.218242_bib1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3322\/caac.21559","article-title":"Epithelial ovarian cancer: evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"Ca-Cancer J. Clin."},{"issue":"7579","key":"10.1016\/j.canlet.2026.218242_bib2","article-title":"Ovarian cancer: beyond resistance","volume":"527","author":"Holmes","year":"2015","journal-title":"Nat"},{"issue":"1","key":"10.1016\/j.canlet.2026.218242_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","article-title":"Advances in ovarian cancer therapy","volume":"81","author":"Cortez","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218242_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1125868","article-title":"Localized chemotherapy approaches and advanced drug delivery strategies: a step forward in the treatment of peritoneal carcinomatosis from ovarian cancer","volume":"13","author":"Breusa","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218242_bib5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive epithelial ovarian cancer survival by histotype and disease stage","volume":"111","author":"Peres","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"issue":"P3","key":"10.1016\/j.canlet.2026.218242_bib6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.semcancer.2022.03.027","article-title":"Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment","volume":"86","author":"Schoutrop","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218242_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12935-023-02854-5","article-title":"Tumor microenvironment in ovarian cancer peritoneal metastasis","volume":"23","author":"Mei","year":"2023","journal-title":"Cancer Cell Int."},{"issue":"2","key":"10.1016\/j.canlet.2026.218242_bib8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1470-2045(20)30591-X","article-title":"Objective responses to first-line neoadjuvant carboplatin\u2013paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial","volume":"22","author":"Morgan","year":"2021","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.canlet.2026.218242_bib9","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.1995.13.12.2961","article-title":"Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a gynecologic oncology group pilot study","volume":"13","author":"Francis","year":"1995","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218242_bib10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2013.04.001","article-title":"Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a gynecologic oncology group study","volume":"130","author":"Landrum","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"0","key":"10.1016\/j.canlet.2026.218242_bib11","first-page":"43","article-title":"Experimental and clinical results with intraperitoneal cisplatin","volume":"12","author":"ten Bokkel Huinink","year":"1985","journal-title":"Semin. Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2026.218242_bib12","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.2217\/fon.10.100","article-title":"Intraperitoneal therapy for peritoneal cancer","volume":"6","author":"Lu","year":"2010","journal-title":"Future Oncol."},{"issue":"20","key":"10.1016\/j.canlet.2026.218242_bib13","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218242_bib14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.addr.2016.07.001","article-title":"Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis - mission possible?","volume":"108","author":"Dakwar","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.canlet.2026.218242_bib15","first-page":"19","article-title":"First experiences with intraperitoneal chemotherapy in ovarian cancer","volume":"11","author":"Gitsch","year":"1990","journal-title":"Eur. J. Gynaecol. Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2026.218242_bib16","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/1097-0142(19940315)73:6<1693::AID-CNCR2820730623>3.0.CO;2-0","article-title":"Evaluation of survival after second\u2010line intraperitoneal cisplatin\u2010based chemotherapy for advanced ovarian cancer","volume":"73","author":"Piver","year":"1994","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.canlet.2026.218242_bib17","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1200\/JCO.2002.20.3.694","article-title":"Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up","volume":"20","author":"Barakat","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2026.218242_bib18","first-page":"265","article-title":"Intraperitoneal cisplatin-mitoxantrone and intravenous ifosfamide combination as first-line treatment of ovarian cancer","volume":"19","author":"Topuz","year":"1998","journal-title":"Eur. J. Gynaecol. Oncol."},{"issue":"26","key":"10.1016\/j.canlet.2026.218242_bib19","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.canlet.2026.218242_bib20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF01410140","article-title":"Salvage intraperitoneal therapy of small-volume residual ovarian cancer: impact of pretreatment finding of peritoneal carcinomatosis on the surgical complete response rate","volume":"118","author":"Markman","year":"1992","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.canlet.2026.218242_bib21","doi-asserted-by":"crossref","first-page":"9545","DOI":"10.3390\/ijms13089545","article-title":"Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death","volume":"13","author":"Castells","year":"2012","journal-title":"Int. J. Mol. Sci."},{"issue":"0","key":"10.1016\/j.canlet.2026.218242_bib22","doi-asserted-by":"crossref","first-page":"viii1","DOI":"10.1093\/annonc\/mdx444","article-title":"Immunotherapy in ovarian cancer","volume":"28","author":"Odunsi","year":"2017","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2026.218242_bib23","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/s41416-024-02863-9","article-title":"Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer","volume":"131","author":"Yao","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"0","key":"10.1016\/j.canlet.2026.218242_bib24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejca.2015.12.016","article-title":"Targeting the tumour microenvironment in ovarian cancer","volume":"56","author":"Hansen","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.canlet.2026.218242_bib25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","article-title":"Turning foes to friends: targeting cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.canlet.2026.218242_bib26","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.3390\/cancers14112637","article-title":"The role of cancer-associated fibroblasts in ovarian cancer","volume":"14","author":"Zhang","year":"2022","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.canlet.2026.218242_bib27","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2026.218242_bib28","article-title":"The role of CTHRC1 in regulation of multiple signaling and tumor progression and metastasis","author":"Mei","year":"2020","journal-title":"Mediat. Inflamm."},{"issue":"3","key":"10.1016\/j.canlet.2026.218242_bib29","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1084\/jem.20180765","article-title":"Heterotypic CAF-tumor spheroids promote early peritoneal metastasis of ovarian cancer","volume":"216","author":"Gao","year":"2019","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.canlet.2026.218242_bib30","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.ccell.2021.09.003","article-title":"Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms","volume":"39","author":"Hu","year":"2021","journal-title":"Cancer Cell"},{"issue":"0","key":"10.1016\/j.canlet.2026.218242_bib31","article-title":"Cancer-associated fibroblasts: origin, function, imaging, and therapeutic targeting","volume":"189","author":"Rimal","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.canlet.2026.218242_bib32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41419-024-07270-9","article-title":"Disease, ERG mediates the differentiation of hepatic progenitor cells towards immunosuppressive PDGFR\u03b1+ cancer-associated fibroblasts during hepatocarcinogenesis","volume":"16","author":"Bai","year":"2025","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.canlet.2026.218242_bib33","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","article-title":"Fibroblast heterogeneity and immunosuppressive environment in human breast cancer","volume":"33","author":"Costa","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.canlet.2026.218242_bib34","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41467-018-03348-z","article-title":"miR200-regulated CXCL12\u03b2 promotes fibroblast heterogeneity and immunosuppression in ovarian cancers","volume":"9","author":"Givel","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.canlet.2026.218242_bib35","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41467-019-14134-w","article-title":"Cancer-associated fibroblast heterogeneity in axillary lymph nodes drives metastases in breast cancer through complementary mechanisms","volume":"11","author":"Pelon","year":"2020","journal-title":"Nat. Commun."},{"issue":"16","key":"10.1016\/j.canlet.2026.218242_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk8805","article-title":"Spatiotemporal architecture of immune cells and cancer-associated fibroblasts in high-grade serous ovarian carcinoma","volume":"10","author":"Xu","year":"2024","journal-title":"Sci. Adv."},{"issue":"4","key":"10.1016\/j.canlet.2026.218242_bib37","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth Factor-\u03b2 signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.canlet.2026.218242_bib38","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1158\/1078-0432.CCR-10-2429","article-title":"TGF-\u03b2 blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models","volume":"17","author":"Liao","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.canlet.2026.218242_bib39","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1073\/pnas.1818357116","article-title":"Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma","volume":"116","author":"Zhao","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"0","key":"10.1016\/j.canlet.2026.218242_bib40","first-page":"2516","article-title":"Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels","volume":"4","author":"Vikash P","year":"2013","journal-title":"Nat. Commun."},{"issue":"0","key":"10.1016\/j.canlet.2026.218242_bib41","article-title":"Amplification of cGAS-STING pathway with \u201csingle-molecule multitarget\u201d nanoparticles for chemo-immunotherapy of ovarian cancer","volume":"323","author":"Fu","year":"2025","journal-title":"Biomaterials"},{"issue":"0","key":"10.1016\/j.canlet.2026.218242_bib42","article-title":"STING pathway activation with cisplatin polyprodrug nanoparticles for chemo-immunotherapy in ovarian cancer","volume":"381","author":"Fu","year":"2025","journal-title":"J. Contr. Release"},{"issue":"6","key":"10.1016\/j.canlet.2026.218242_bib43","article-title":"STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer","volume":"9","author":"Joon","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"0","key":"10.1016\/j.canlet.2026.218242_bib44","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.ejmech.2018.08.065","article-title":"Chlorambucil-conjugated platinum (IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo","volume":"157","author":"Ma","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.canlet.2026.218242_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2024.110229","article-title":"Nanomedicine-based targeting delivery systems for peritoneal cavity localized therapy: a promising treatment of ovarian cancer and its peritoneal metastasis","volume":"36","author":"Liu","year":"2025","journal-title":"Chin. Chem. Lett."},{"issue":"8","key":"10.1016\/j.canlet.2026.218242_bib46","doi-asserted-by":"crossref","first-page":"10102","DOI":"10.1021\/acsami.1c23166","article-title":"Interfaces, sequential delivery of quercetin and paclitaxel for the fibrotic tumor microenvironment remodeling and chemotherapy potentiation via a dual-targeting hybrid micelle-in-liposome system","volume":"14","author":"Duan","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"5","key":"10.1016\/j.canlet.2026.218242_bib47","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1021\/acsabm.0c00242","article-title":"Matrix metalloproteinase-responsive PEGylated lipid nanoparticles for controlled drug delivery in the treatment of rheumatoid arthritis","volume":"3","author":"He","year":"2020","journal-title":"ACS Appl. Bio Mater."},{"issue":"40","key":"10.1016\/j.canlet.2026.218242_bib48","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1002\/adma.201506312","article-title":"Inflammation-triggered cancer immunotherapy by programmed delivery of CpG and Anti-PD1 antibody","volume":"28","author":"Wang","year":"2016","journal-title":"Adv. Mater."},{"issue":"0","key":"10.1016\/j.canlet.2026.218242_bib49","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.actbio.2019.05.007","article-title":"Cisplatin-loaded polymeric complex micelles with a modulated drug\/copolymer ratio for improved in vivo performance","volume":"92","author":"Chen","year":"2019","journal-title":"Acta Biomater."},{"issue":"0","key":"10.1016\/j.canlet.2026.218242_bib50","article-title":"Micelle-contained and PEGylated hybrid liposomes of combined gemcitabine and cisplatin delivery for enhancing antitumor activity","volume":"602","author":"Liu","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"29","key":"10.1016\/j.canlet.2026.218242_bib51","doi-asserted-by":"crossref","first-page":"18963","DOI":"10.1021\/acsnano.4c02312","article-title":"Injectable nanocomposite hydrogels improve intraperitoneal Co-delivery of chemotherapeutics and immune checkpoint inhibitors for enhanced peritoneal metastasis therapy","volume":"18","author":"Shu","year":"2024","journal-title":"ACS Nano"},{"issue":"8","key":"10.1016\/j.canlet.2026.218242_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2022.108104","article-title":"Local sustained release of PD-1 monoclonal antibody and lenvatinib by thermo-sensitive hydrogel for improving tumor immunotherapy","volume":"4","author":"Zhai","year":"2023","journal-title":"Chin. Chem. Lett."},{"issue":"0","key":"10.1016\/j.canlet.2026.218242_bib53","article-title":"Localized controlled release of bevacizumab and doxorubicin by thermo-sensitive hydrogel for normalization of tumor vasculature and to enhance the efficacy of chemotherapy","volume":"572","author":"Darge","year":"2019","journal-title":"Int. J. Pharm."},{"issue":"9","key":"10.1016\/j.canlet.2026.218242_bib54","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009327","article-title":"Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockade","volume":"12","author":"Mei","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218242_bib55","series-title":"Mechanism of Hepatocellular Carcinoma Resistance to Cisplatin via CaN-mediated Mitochondrial Turnover Pathway [D]","author":"Han","year":"2024"},{"issue":"0","key":"10.1016\/j.canlet.2026.218242_bib56","article-title":"Therapeutic strategies to overcome cisplatin resistance in ovarian cancer","volume":"232","author":"Song","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"0","key":"10.1016\/j.canlet.2026.218242_bib57","first-page":"30","article-title":"Intracellular glutathione-depleting polymeric micelles for cisplatin prodrug delivery to overcome cisplatin resistance of cancers","volume":"273","author":"Yu","year":"2018","journal-title":"J. Contr. Release"},{"issue":"0","key":"10.1016\/j.canlet.2026.218242_bib58","first-page":"119","article-title":"Overcoming resistance to cisplatin by inhibition of glutathione S-transferases (GSTs) with ethacraplatin micelles in vitro and in vivo","volume":"144","author":"Shuyi","year":"2017","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.canlet.2026.218242_bib59","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3892\/ol.2015.3879","article-title":"The effects of buthionine sulfoximine on the proliferation and apoptosis of biliary tract cancer cells induced by cisplatin and gemcitabine","volume":"11","author":"Qiwei","year":"2016","journal-title":"Oncol. Lett."},{"issue":"0","key":"10.1016\/j.canlet.2026.218242_bib60","first-page":"62","article-title":"Possible involvement of glutathione S-transferases in imazamox detoxification in an imidazolinone-resistant sunflower hybrid","volume":"221","author":"Dobrinka","year":"2017","journal-title":"J. Plant Physiol."},{"issue":"24","key":"10.1016\/j.canlet.2026.218242_bib61","doi-asserted-by":"crossref","first-page":"8574","DOI":"10.1021\/jm201131n","article-title":"Inhibition of glutathione S-transferase M1 by new gabosine analogues is essential for overcoming cisplatin resistance in lung cancer cells","volume":"54","author":"Chie-Hong","year":"2011","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.canlet.2026.218242_bib62","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/s41419-019-2081-4","article-title":"Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells","volume":"10","author":"Markus","year":"2019","journal-title":"Cell Death Dis."},{"issue":"0","key":"10.1016\/j.canlet.2026.218242_bib63","first-page":"50","article-title":"ROS signalling in the biology of cancer","volume":"80","author":"Jennifer N","year":"2017","journal-title":"Semin. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218242_bib64","first-page":"30","article-title":"Effects of bismuth oxide nanoparticles, cisplatin and baicalein-rich fraction on ROS generation in proton beam irradiated human Colon carcinoma cells, pol","volume":"28","author":"Sisin","year":"2022","journal-title":"J. Med. Phys. Eng"},{"issue":"11","key":"10.1016\/j.canlet.2026.218242_bib65","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1038\/s41416-024-02671-1","article-title":"Cancer-associated fibroblasts expressing fibroblast activation protein and podoplanin in non-small cell lung cancer predict poor clinical outcome","volume":"130","author":"Mathieson","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2026.218242_bib66","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/jth.15544","article-title":"Podoplanin promotes tumor growth, platelet aggregation, and venous thrombosis in murine models of ovarian cancer","volume":"20","author":"Sasano","year":"2022","journal-title":"J. Thromb. Haemostasis"},{"issue":"0","key":"10.1016\/j.canlet.2026.218242_bib67","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.matbio.2017.12.009","article-title":"Thrombospondin-1 regulation of latent TGF-\u03b2 activation: a therapeutic target for fibrotic disease","volume":"68\u201369","author":"Murphy-Ullrich","year":"2018","journal-title":"Matrix Biol."},{"issue":"0","key":"10.1016\/j.canlet.2026.218242_bib68","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.matbio.2024.01.005","article-title":"Thrombospondin-1 promotes mechanical stress-mediated ligamentum flavum hypertrophy through the TGF\u03b21\/Smad3 signaling pathway","volume":"127","author":"Zhao","year":"2024","journal-title":"Matrix Biol."},{"issue":"14","key":"10.1016\/j.canlet.2026.218242_bib69","doi-asserted-by":"crossref","first-page":"13611","DOI":"10.1021\/acsnano.3c02272","article-title":"Transforming cancer-associated fibroblast barrier into drug depots to boost chemo-immunotherapy in \u201cshooting fish in a barrel\u201d pattern","volume":"17","author":"Yuan","year":"2023","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.canlet.2026.218242_bib70","article-title":"RGS3 acts as a tumor promoter by facilitating the regulation of the TGF-\u03b2 signaling pathway and promoting EMT in ovarian cancer","volume":"11","author":"Wang","year":"2025","journal-title":"Cell Death Discov."},{"issue":"4","key":"10.1016\/j.canlet.2026.218242_bib71","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/17425247.2020.1736551","article-title":"Intraperitoneal chemotherapy for peritoneal metastases: an expert opinion","volume":"17","author":"Wim","year":"2020","journal-title":"Expet Opin. Drug Deliv."},{"issue":"4","key":"10.1016\/j.canlet.2026.218242_bib72","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000333803","article-title":"Impact of intraperitoneal chemotherapy after gastrectomy with positive cytological findings in peritoneal washings","volume":"47","year":"2011","journal-title":"Eur. Surg. Res."},{"issue":"3","key":"10.1016\/j.canlet.2026.218242_bib73","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jconrel.2013.09.013","article-title":"Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles","volume":"172","author":"Mark J","year":"2013","journal-title":"J. Contr. Release"},{"issue":"19","key":"10.1016\/j.canlet.2026.218242_bib74","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2300706120","article-title":"Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells","volume":"120","author":"Gu","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.canlet.2026.218242_bib75","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41467-020-20723-x","article-title":"Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles","volume":"12","author":"Wei","year":"2021","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.canlet.2026.218242_bib76","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1172\/JCI84427","article-title":"The impact of hypoxia on tumor-associated macrophages","volume":"126","author":"Henze","year":"2016","journal-title":"J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.canlet.2026.218242_bib77","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201806202","article-title":"Cocktail strategy based on spatio\u2010temporally controlled nano device improves therapy of breast cancer","volume":"31","author":"Lang","year":"2019","journal-title":"Adv. Mater."},{"issue":"11","key":"10.1016\/j.canlet.2026.218242_bib78","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41577-024-01040-6","article-title":"A guide to adaptive immune memory","volume":"24","author":"Lam","year":"2024","journal-title":"Nat. Rev. Immunol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526000054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526000054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:39:24Z","timestamp":1792096764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526000054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":78,"alternative-id":["S0304383526000054"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218242","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Pt (IV)\/losartan\/immunotherapy Co-delivery thermosensitive gel synergizes STING activation and cancer-associated fibroblast inhibition for ovarian cancer chemoimmunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218242"}}